News

Filter: Press Releases

CN Bio Innovations announces license of worldwide rights to Hepatitis B programme from Bristol-Myers Squibb

London, UK, April 5 2017: CN Bio Innovations Limited announces that it has licensed from Bristol-Myers Squibb Company a Hepatitis B drug discovery programme comprising several series of small molecule antiviral compounds. The exclusive agreement enables CN Bio to undertake discovery, development and commercialisation of the antiviral compounds to create a combination treatment for chronic Hepatitis… Read more »

READ MORE

Dr Emma Sceats of organ-on-a-chip firm CN Bio Innovations wins Innovate UK’s infocus Women in Innovation award

Welwyn Garden City, UK- 15th November 2016: Following a nationwide competition, CEO of London bioengineering firm CN Bio Innovations Dr Emma Sceats has been named as a winner of Innovate UK’s infocus Women in Innovation award. The awards will be celebrated as part of the Lloyds National Business Awards in London tonight. Innovate UK’s infocus… Read more »

READ MORE

CN Bio Innovations announces research collaboration with Alnylam

CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics for liver diseases and infection, is pleased to announce the commencement of a research collaboration with Alnylam Pharmaceuticals. Research relevant to the advancement of Alnylam’s RNAi therapeutics will be performed using CN Bio’s human liver-on-a-chip platform, LiverChip.

READ MORE

CN Bio announces opening of new Biosafety Level 3 facility

CN Bio Innovations Ltd (CN Bio), an expert in developing human biomimetic platforms to test and develop therapeutics for serious diseases, announced today the opening of a new facility, including state-of-the-art Biosafety level 3 (BSL-3) laboratories, in Welwyn Garden City, UK.  The BSL-3 laboratories will be dedicated to research, development and drug discovery alliance programmes… Read more »

READ MORE

Imperial College London to present first public HBV data from CN Bio in vitro liver model

CN Bio Innovations Ltd (CN Bio), an expert in developing human biomimetic platforms to test and develop therapeutics for serious diseases, has announced that data from its research collaboration with Imperial College London, where the team are analysing a novel human, full-viral-lifecycle model of Hepatitis B, will be the subject of oral and poster presentations… Read more »

READ MORE

CN Bio Innovations marks World Hepatitis Day by signing research agreement with Imperial College London

Collaboration will develop and further validate CN Bio’s in vitro model of Hepatitis B liver infection Oxford, UK, 28 July 2014: CN Bio Innovations Ltd (CN Bio), an expert in developing leading edge human biomimetic platforms to test and develop therapeutics for serious diseases, announced today that it has signed a research agreement with Imperial… Read more »

READ MORE

Zyoxel Ltd to become CN Bio Innovations Ltd

Zyoxel, an expert in advanced in vitro 3D liver models for drug discovery and drug testing, has today announced it is changing its name to CN Bio Innovations Ltd  (CNBIO). The move is part of a strategic rebrand designed to closer align the organisation with its Hong Kong-based holding company, CN Innovations Holdings Limited (CNI)…. Read more »

READ MORE